Clinical Trials Browser

Interventional × MSI-H/dMMR Solid Tumors × 90 days × Clear all

NCT03736889 2026-04-22

Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors

Phase 2 Recruiting

Other solid neoplasm

MSI-H/dMMR Solid Tumors